Human Microbiome Market by Disease (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder), Application (Therapeutic, Diagnostic) & by Product (Probiotic, Prebiotic, Food, Medical Food, Supplement, Device, Drug) – Global Forecast to 2023
Dallas, TX -- (SBWIRE) -- 10/01/2014 -- According to the new market research report The "Human Microbiome Market by Disease (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder), Application (Therapeutic, Diagnostic), Product (Probiotic, Prebiotic, Food, Medical Food, Supplement, Device, Drug) - Global Forecast to 2023", published by MarketsandMarkets, provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the Human Microbiome Market along with the estimates and forecasts of the revenue and share analysis.
Browse 40 Market Data Tables
150 Pages and in-depth TOC on “Human Microbiome Market” http://www.marketsandmarkets.com/Market-Reports/human-microbiome-market-37621904.html
Early buyers will receive 10% customization on this report.
The Human Microbiome Market is expected to reach $658 Million by 2023 from $294 Million in 2019 growing at a CAGR of 22.3% during the forecast period (2019-2023).
The human microbiome market is segmented by application, disease, product, and geography.
The human microbiome market is expected to be valued as $294 million in 2019 and is poised to grow at a CAGR of 22.3% within the forecast period of 2019-2023. The market is driven by growing incidences of unhealthy lifestyle diseases, and increase in occurrence of autoimmune disorders. However, government regulation and lack of detailed research may restrain the growth of this market to an extent. Investing in probiotic and prebiotic products, medical foods, drugs, and devices will prove fruitful for companies in the future.
The applications segment is further subdivided into therapeutics and diagnostics. Therapeutics may be the leading segment, owing to growing population and diseases.
Currently, the diagnostics segment has fewer products in the pipeline than the therapeutics segment.
Further Inquiry: http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=37621904
The disease market is subdivided into the obesity, diabetes, autoimmune disorders, cancer, acute diarrhea, mental disorders and others segments. Of these, obesity and acute diarrhea are expected to be the leading segments; acute diarrhea is expected to show the fastest growth . This growth will driven by the rise in lifestyle diseases, aging population and high adoption rates of approved products.
The products segment is subdivided into probiotics, prebiotics, foods, medical foods, other supplements, devices, and drugs. Growth in these segments will be majorly driven due to use of probiotics and prebiotics for maintaining gut flora to avoid lifestyle diseases.
To Purchase: http://www.marketsandmarkets.com/Purchase/purchase_report1.asp?id=37621904
The geographic analysis reveals that Europe will account for the largest share within the forecast period of 2019 to 2023, due to high acceptance of probiotic and prebiotic produtcs. Asia is expected to be a profitable region for the human microbiome market and poised to grow at a healthy CAGR in the forecast period. North America will show a low market share; however, it is expected to grow at a high CAGR from 2019 to 2023.
The key players in the human microbiome market are Enterome Bioscience (France), Yakult Honsha Co., Ltd. (Japan), E. I. Du Pont de Nemours and company (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome, Inc. ( U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences, Inc. (U.S.), Osel, Inc. (U.S.), and Merck & Co, Inc. (U.S.)
Browse related reports
Human Insulin Market by Product Type [Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2019http://www.marketsandmarkets.com/Market-Reports/human-insulin-market-229295783.html
Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals, including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, healthcare IT semiconductor and electronics, and telecommunications and IT.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas, TX 75252
Visit MarketsandMarkets Blog http://www.marketsandmarketsblog.com/market-reports/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets